Evaluating neopterin levels in elderly ICU patients
Neopterin on Admission to the ICU: an Immunological Biomarker That Could Help Admission Decisions by Identifying Elderly Patients (≥80 Years) Able to Survive an ICU Stay Without Disability
This study is testing if measuring neopterin levels in patients aged 80 and older in the ICU can help doctors make better decisions about their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 326 (estimated) |
| Ages | 80 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT05233267 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the levels of neopterin in patients aged 80 years and older who are admitted to the intensive care unit (ICU). The study seeks to determine if neopterin can serve as a predictive biomarker to help intensive care physicians make informed decisions about patient management. Given the increasing number of elderly patients in ICUs, the research addresses the need for reliable criteria to identify those who may benefit from intensive care. By analyzing blood samples taken upon admission, the study hopes to improve survival rates and maintain autonomy for this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 80 years or older who have been admitted to the ICU within the last 24 hours.
Not a fit: Patients who are hospitalized for scheduled surgeries or have active solid cancers or autoimmune diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable biomarker to guide treatment decisions for elderly patients in intensive care, potentially improving their outcomes.
How similar studies have performed: While there is limited data on the use of neopterin in this specific context, the approach of using biomarkers for patient stratification in critical care is gaining traction and has shown promise in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 80 years old * Admission to intensive care unit before 24 hours * Non opposition expressed by the participant or its relative/trusty person, or emergency inclusion procedure Exclusion Criteria: * Hospitalisation for a scheduled surgery * New admission within a month before previous stay to intensive care unit * Active solid cancer or malignant hemopathy * Immunosuppressant treatment (including corticotherapy \> 5 mg/d) * Autoimmune disease * Tutorship or curatorship
Where this trial is running
Paris
- Hôpital Saint-Antoine / Service de réanimation — Paris, France (Recruiting)
Study contacts
- Principal investigator: Hélène VALLET, MD — Hôpital Saint-Antoine - APHP
- Study coordinator: Hélène VALLET, MD
- Email: helene.vallet@aphp.fr
- Phone: 01 49 28 20 42
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.